BIVI

NASDAQ 已收盘

BioVie

0.80 USD
▼-0.11-12.07%
盘后 0.94 +17.41%
2026-11-20
市值
$8.58M
市盈率
—
EPS
-2.82
股息率
—
52 周区间
0.75 – 3.79
成交量
399.58K
Beta
0.80
目标价
5.26
52W 低 0.7552W 高 3.79
价格走势

公司简介

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to mo...